| Autor: |
Alderuccio JP; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Florindez JA; Department of Medicine, Division of Hospital Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Reis IM; Department of Public Health Science, University of Miami Miller School of Medicine, Miami, FL 33136, USA.; Sylvester Biostatistics and Bioinformatics Core Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Zhao W; Sylvester Biostatistics and Bioinformatics Core Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Lossos IS; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.; Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. |
| Abstrakt: |
A considerable number of patients with extranodal marginal zone lymphoma (EMZL) are diagnosed with stage I disease. Information on treatments and survival by primary location remains limited. We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database to assess treatment, primary location, and survival of patients with stage I EMZL. Results show that 7961 patients met inclusion criteria. Observation (no treatment) was the most common approach (31%) followed by radiation therapy (RT, 23%). The median overall survival (OS) was 17.3 years (95%CI 16.3 to 18.3). Shorter survival was observed in patients with stage I EMZL compared to expected survival in a cohort derived from the general U.S. population matched by sex, age, and calendar year at diagnosis. However, similar survival was observed in RT-treated patients. We identified age ≥ 60 years (SHR = 4.00, 95%CI 3.10-5.15; p < 0.001), higher grade transformation (SHR = 4.63, 95%CI 3.29-6.52; p < 0.001), and primary lung EMZL (SHR = 1.44, 95%CI 1.05-1.96; p = 0.022) as factors associated with shorter lymphoma-specific survival (LSS). Conversely, primary skin location (SHR = 0.50, 95%CI 0.33-0.77; p = 0.002) was associated with longer LSS. Our results support the use of RT as the preferred approach in localized EMZL. |
